CU24493B1 - Complejo de torio dirigido a tejido - Google Patents

Complejo de torio dirigido a tejido

Info

Publication number
CU24493B1
CU24493B1 CU2017000082A CU20170082A CU24493B1 CU 24493 B1 CU24493 B1 CU 24493B1 CU 2017000082 A CU2017000082 A CU 2017000082A CU 20170082 A CU20170082 A CU 20170082A CU 24493 B1 CU24493 B1 CU 24493B1
Authority
CU
Cuba
Prior art keywords
complex
torio
tissue targeted
addition
tissue
Prior art date
Application number
CU2017000082A
Other languages
English (en)
Other versions
CU20170082A7 (es
Inventor
Alan Cuthbertson
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54884033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24493(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer As filed Critical Bayer As
Publication of CU20170082A7 publication Critical patent/CU20170082A7/es
Publication of CU24493B1 publication Critical patent/CU24493B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>La invención provee un complejo dirigido a tejido por acoplamiento de quelantes específicos a porciones de direccionamiento apropiadas, seguido por el agregado de un ión de torio emisor alfa. Además del complejo de torio, se proveen las formulaciones farmacéuticas correspondientes. La invención también se relaciona con la administración de estos complejos particularmente en enfermedades neoplásicas. </p>
CU2017000082A 2014-12-17 2015-12-15 Complejo de torio dirigido a tejido CU24493B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201422512 2014-12-17
PCT/EP2015/079773 WO2016096843A1 (en) 2014-12-17 2015-12-15 Radio-pharmaceutical complexes

Publications (2)

Publication Number Publication Date
CU20170082A7 CU20170082A7 (es) 2017-10-05
CU24493B1 true CU24493B1 (es) 2020-12-17

Family

ID=54884033

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000082A CU24493B1 (es) 2014-12-17 2015-12-15 Complejo de torio dirigido a tejido

Country Status (30)

Country Link
US (2) US20170340759A1 (es)
EP (1) EP3233137A1 (es)
JP (2) JP6821569B2 (es)
KR (1) KR20170094223A (es)
CN (1) CN107278155B (es)
AR (1) AR103063A1 (es)
AU (2) AU2015367722A1 (es)
BR (1) BR112017012841A2 (es)
CA (1) CA2970841A1 (es)
CL (1) CL2017001592A1 (es)
CO (1) CO2017005975A2 (es)
CR (1) CR20170256A (es)
CU (1) CU24493B1 (es)
DO (1) DOP2017000143A (es)
EA (1) EA201791350A9 (es)
EC (1) ECSP17038089A (es)
IL (1) IL252244B (es)
JO (1) JOP20150319B1 (es)
MA (1) MA41176A (es)
MX (1) MX384088B (es)
MY (1) MY194190A (es)
NI (1) NI201700076A (es)
PE (2) PE20171181A1 (es)
PH (1) PH12017501125A1 (es)
SG (1) SG11201704917XA (es)
TN (1) TN2017000255A1 (es)
TW (1) TWI654179B (es)
UA (1) UA125369C2 (es)
UY (1) UY36453A (es)
WO (1) WO2016096843A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202009424TA (en) * 2016-03-24 2020-11-27 Bayer Pharma AG Radio-pharmaceutical complexes
CN109689115A (zh) * 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
WO2018153975A1 (en) 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
IL269763B2 (en) * 2017-03-30 2024-08-01 Univ Cornell Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
US20220125960A1 (en) 2019-02-21 2022-04-28 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
WO2020169538A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
WO2021013978A1 (en) 2019-07-25 2021-01-28 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158804B2 (en) * 2007-01-11 2012-04-17 Ge Healthcare As Chelating agents
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
TW201627286A (zh) 2016-08-01
KR20170094223A (ko) 2017-08-17
MX384088B (es) 2025-03-14
CU20170082A7 (es) 2017-10-05
EA201791350A9 (ru) 2020-02-11
JP7160961B2 (ja) 2022-10-25
JP2021063108A (ja) 2021-04-22
BR112017012841A2 (pt) 2018-04-10
CL2017001592A1 (es) 2018-03-16
AU2015367722A1 (en) 2017-06-08
CO2017005975A2 (es) 2017-11-30
EP3233137A1 (en) 2017-10-25
CN107278155B (zh) 2021-03-30
JP2018506513A (ja) 2018-03-08
UY36453A (es) 2016-07-29
PE20230829A1 (es) 2023-05-19
TWI654179B (zh) 2019-03-21
TN2017000255A1 (en) 2018-10-19
AU2021202665B2 (en) 2023-04-27
NI201700076A (es) 2017-09-22
JOP20150319B1 (ar) 2021-08-17
PE20171181A1 (es) 2017-08-22
MX2017008093A (es) 2018-02-09
AR103063A1 (es) 2017-04-12
CR20170256A (es) 2017-08-11
DOP2017000143A (es) 2017-07-15
MA41176A (fr) 2017-10-24
JP6821569B2 (ja) 2021-01-27
IL252244B (en) 2020-10-29
US20210322583A1 (en) 2021-10-21
CN107278155A (zh) 2017-10-20
CA2970841A1 (en) 2016-06-23
EA201791350A1 (ru) 2017-12-29
UA125369C2 (uk) 2022-03-02
WO2016096843A1 (en) 2016-06-23
MY194190A (en) 2022-11-18
US20170340759A1 (en) 2017-11-30
AU2021202665A1 (en) 2021-05-27
IL252244A0 (en) 2017-07-31
SG11201704917XA (en) 2017-07-28
PH12017501125A1 (en) 2017-11-27
ECSP17038089A (es) 2017-07-31

Similar Documents

Publication Publication Date Title
CU24493B1 (es) Complejo de torio dirigido a tejido
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2018016193A (es) Métodos para el tratamiento del cáncer de ovario.
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
CL2019000844A1 (es) Compuesto de piridina.
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MY171945A (en) Compositions, formulations and methods for treating ocular diseases
TW201613901A (en) New compounds
UY36075A (es) Derivados de tubulisina
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
CL2017001310A1 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
BR112017009289A2 (pt) métodos de administrar composições de amantadina
MX2017015279A (es) Exasomas y su uso como vacunas.
MX383975B (es) Derivado de anillo fusionado como inhibidor del receptor a2a
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
PH12018501166B1 (en) Concentrated gibberellin solution formulations